Skip to main
ILMN

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 36%
Hold 36%
Sell 7%
Strong Sell 7%

Bulls say

Illumina is well-positioned in the clinical sequencing market due to its dominant market share and strong financials. The company has a focused strategy for balancing pricing and profitability, while also investing in new products and potential subscription models. However, they may face challenges in the research market and China, which could impact their rating and stock price.

Bears say

Illumina is the market leader in next-generation sequencing, but faces potential headwinds from competitors such as Roche in the MRD field. While the company has multiple growth levers, there is uncertainty around whether they will actually reach growth rates above the mid-teens% as management has suggested. Additionally, Illumina faces sustainability concerns around product environmental footprint, human capital management, and data privacy/cybersecurity, which may negatively impact its reputation and profitability.

Illumina (ILMN) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Hold based on their latest research and market trends.

According to 14 analysts, Illumina (ILMN) has a Hold consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $189.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $189.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.